Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesis is that eltrombopag given to patients with moderate to very
severe aplastic anemia will result in an increase in platelet counts. The investigators
hypothesize that in patients with moderate to very severe aplastic anemia, treatment with
eltrombopag will lead to fewer platelet transfusions, red blood cell transfusions, and fewer
bleeding events. The investigators hypothesize that in patients with moderate to very severe
aplastic anemia, eltrombopag will have an acceptable toxicity rate <3%, at doses that result
in increased platelet counts. Finally the investigators hypothesize that plasma eltrombopag
levels in peripheral blood will correlate with improved platelet counts.